Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.

Patients with BRAFV600-mutant glioma received vemurafenib 960 mg twice per day continuously...Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including malignant diffuse glioma (n = 11; six glioblastoma and five anaplastic astrocytoma),...Best response in patients with malignant diffuse glioma (n = 11) included one patient with PR, five with SD (two of whom had SD that lasted ≥ 6 months, thus meeting the definition for clinical benefit),...